
News|Articles|December 1, 2012
Early therapy with basal insulin does not reduce cardiovascular outcomes in dysglycemic patients
Early initiation of basal insulin did not impact cardiovascular outcomes compared to standard management of glucose in patients with type 2 diabetes or elevated fasting glucose with cardiovascular risk factors.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA approves first postmenopausal libido treatment, Addyi
2
What IRA drug prices will mean for PBMs, health plans and patients
3
Biosimilars in 2025: A year of firsts
4
Looking ahead: What the MHE 2025 State of the Industry survey tells us about 2026
5






















































